Literature DB >> 30830537

Fluorescent Tissue Assessment of Colorectal Cancer Liver Metastases Ablation Zone: A Potential Real-Time Biomarker of Complete Tumor Ablation.

Vlasios S Sotirchos1, Sho Fujisawa2, Efsevia Vakiani3, Stephen B Solomon4, Katia O Manova-Todorova2, Constantinos T Sofocleous5.   

Abstract

BACKGROUND: This study aimed to evaluate whether rapid fluorescent tissue examination immediately after colorectal cancer liver metastasis (CLM) ablation correlates with standard pathologic and immunohistochemical (IHC) assessments.
METHODS: This prospective, National Institutes of Health-supported study enrolled 34 consecutive patients with 53 CLMs ablated between January 2011 and December 2014. Immediately after ablation, core needle sampling of the ablation zone was performed. Tissue samples were evaluated with fluorescent viability (MitoTracker Red) and nuclear (Hoechst) stains. Confocal microscope imaging was performed within 30 min after ablation. The same samples were subsequently fixed and stained with hematoxylin and eosin (H&E). Identified tumor cells underwent IHC staining for proliferation (Ki67) and viability (OxPhos). The study pathologist, blinded to the H&E and IHC assessment, evaluated the fluorescent images separately to detect viable tumor cells. Sensitivity, specificity, and overall concordance of the fluorescent versus H&E and IHC assessments were calculated.
RESULTS: A total of 63 tissue samples were collected and processed. The overall concordance rate between the immediate fluorescent and the subsequent H&E and IHC assessments was 94% (59/63). The fluorescent assessment sensitivity and specificity for the identification of tumor cells were respectively 100% (18/18) and 91% (41/45).
CONCLUSIONS: The study showed a high concordance rate between the immediate fluorescent assessment and the standard H&E and IHC assessment of the ablation zone. Given the documented prognostic value of ablation zone tissue characteristics for outcomes after ablation of CLM, the fluorescent assessment offers a potential intra-procedural biomarker of complete tumor ablation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30830537      PMCID: PMC6839687          DOI: 10.1245/s10434-018-07133-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  31 in total

1.  Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO-1-stained islets.

Authors:  Daniel J Boffa; John Waka; Dolca Thomas; Sungwook Suh; Kevin Curran; Vijay K Sharma; Melissa Besada; Thangamani Muthukumar; Hua Yang; Manikkam Suthanthiran; Katia Manova
Journal:  Transplantation       Date:  2005-04-15       Impact factor: 4.939

2.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

3.  Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.

Authors:  Vlasios S Sotirchos; Lydia M Petrovic; Mithat Gönen; David S Klimstra; Richard K G Do; Elena N Petre; Alessandra R Garcia; Afsar Barlas; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Lynn A Brody; Ronald P DeMatteo; Nancy E Kemeny; Stephen B Solomon; Katia O Manova-Todorova; Constantinos T Sofocleous
Journal:  Radiology       Date:  2016-03-24       Impact factor: 11.105

4.  Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.

Authors:  S N Goldberg; G S Gazelle; C C Compton; P R Mueller; K K Tanabe
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

5.  Real-time in vivo assessment of radiofrequency ablation of human colorectal liver metastases using diffuse reflectance spectroscopy.

Authors:  E Tanis; J W Spliethoff; D J Evers; G C Langhout; P Snaebjornsson; W Prevoo; B H W Hendriks; T J M Ruers
Journal:  Eur J Surg Oncol       Date:  2015-12-23       Impact factor: 4.424

6.  Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases.

Authors:  Sho Fujisawa; Yevgeniy Romin; Afsar Barlas; Lydia M Petrovic; Mesruh Turkekul; Ning Fan; Ke Xu; Alessandra R Garcia; Sebastien Monette; David S Klimstra; Joseph P Erinjeri; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous
Journal:  Cytotechnology       Date:  2013-09-25       Impact factor: 2.058

7.  Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness.

Authors:  E Ronan Ryan; Constantinos T Sofocleous; Heiko Schöder; Jorge A Carrasquillo; Sadek Nehmeh; Steven M Larson; Raymond Thornton; Robert H Siegelbaum; Joseph P Erinjeri; Stephen B Solomon
Journal:  Radiology       Date:  2013-04-05       Impact factor: 11.105

8.  Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression.

Authors:  Nikol Snoeren; Joost Huiskens; Arjen M Rijken; Richard van Hillegersberg; Arian R van Erkel; Gerrit D Slooter; Joost M Klaase; Petrousjka M van den Tol; Fibo J W Ten Kate; Maarten C Jansen; Thomas M van Gulik
Journal:  Ann Surg Oncol       Date:  2011-05-18       Impact factor: 5.344

9.  PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.

Authors:  Etay Ziv; Michael Bergen; Hooman Yarmohammadi; F Ed Boas; E Nadia Petre; Constantinos T Sofocleous; Rona Yaeger; David B Solit; Stephen B Solomon; Joseph P Erinjeri
Journal:  Oncotarget       Date:  2017-04-04

10.  Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.

Authors:  Constantinos T Sofocleous; Sandeep K Garg; Perry Cohen; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Robert J Downey; William D Travis; Stephen B Solomon
Journal:  Ann Surg Oncol       Date:  2013-07-30       Impact factor: 4.339

View more
  6 in total

1.  ASO Author Reflections: Immediate Fluorescent Tissue Assessment-The 'Frozen Section' for Tumor Ablation?

Authors:  Vlasios S Sotirchos; Constantinos T Sofocleous
Journal:  Ann Surg Oncol       Date:  2019-05-30       Impact factor: 5.344

2.  Radiofrequency and microwave ablation in a porcine liver model: non-contrast CT and ultrasound radiologic-pathologic correlation.

Authors:  Timothy J Ziemlewicz; J Louis Hinshaw; Meghan G Lubner; Emily A Knott; Bridgett J Willey; Fred T Lee; Christopher L Brace
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

3.  3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases.

Authors:  Nikiforos Vasiniotis Kamarinos; Mithat Gonen; Vlasios Sotirchos; Elena Kaye; Elena N Petre; Stephen B Solomon; Joseph P Erinjeri; Etay Ziv; Assen Kirov; Constantinos T Sofocleous
Journal:  Int J Hyperthermia       Date:  2022       Impact factor: 3.753

4.  Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?

Authors:  Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Sho Fujisawa; Mithat Gonen; Ning Fan; Yevgeniy Romin; Richard K G Do; Etay Ziv; Joseph P Erinjeri; Elena N Petre; Vlasios S Sotirchos; Juan C Camacho; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous
Journal:  J Vasc Interv Radiol       Date:  2021-11-17       Impact factor: 3.682

Review 5.  The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease.

Authors:  Dimitrios K Filippiadis; Georgios Velonakis; Alexis Kelekis; Constantinos T Sofocleous
Journal:  Diagnostics (Basel)       Date:  2021-02-14

Review 6.  Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin.

Authors:  Giovanni Mauri; Lorenzo Monfardini; Andrea Garnero; Maria Giulia Zampino; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Marco Busso; Carlo Gazzera; Paolo Fonio; Andrea Veltri; Marco Calandri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.